CA1312287C - Substituted 2-aminobenzothiazoles and derivatives useful as cerebrovascular agents - Google Patents

Substituted 2-aminobenzothiazoles and derivatives useful as cerebrovascular agents

Info

Publication number
CA1312287C
CA1312287C CA000558374A CA558374A CA1312287C CA 1312287 C CA1312287 C CA 1312287C CA 000558374 A CA000558374 A CA 000558374A CA 558374 A CA558374 A CA 558374A CA 1312287 C CA1312287 C CA 1312287C
Authority
CA
Canada
Prior art keywords
hydrogen
substituted
amino
alkyl
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CA000558374A
Other languages
English (en)
French (fr)
Inventor
Graham Johnson
Michael Raymond Pavia
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Warner Lambert Co LLC
Original Assignee
Warner Lambert Co LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co LLC filed Critical Warner Lambert Co LLC
Application granted granted Critical
Publication of CA1312287C publication Critical patent/CA1312287C/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00Anaesthetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Anesthesiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Steroid Compounds (AREA)
CA000558374A 1987-03-16 1988-02-08 Substituted 2-aminobenzothiazoles and derivatives useful as cerebrovascular agents Expired - Lifetime CA1312287C (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US2642887A 1987-03-16 1987-03-16
US07/143,107 US4826860A (en) 1987-03-16 1988-01-25 Substituted 2-aminobenzothiazoles and derivatives useful as cerebrovascular agents
US026,428 1988-01-25
US143,107 1988-01-25

Publications (1)

Publication Number Publication Date
CA1312287C true CA1312287C (en) 1993-01-05

Family

ID=26701234

Family Applications (1)

Application Number Title Priority Date Filing Date
CA000558374A Expired - Lifetime CA1312287C (en) 1987-03-16 1988-02-08 Substituted 2-aminobenzothiazoles and derivatives useful as cerebrovascular agents

Country Status (8)

Country Link
US (1) US4826860A (el)
EP (1) EP0282971B1 (el)
JP (1) JP2602275B2 (el)
AT (1) ATE116134T1 (el)
CA (1) CA1312287C (el)
DE (1) DE3852555T2 (el)
ES (1) ES2065895T3 (el)
GR (1) GR3015466T3 (el)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2619712B1 (fr) * 1987-08-25 1990-08-31 Rhone Poulenc Sante Application de l'amino-2 trifluoromethoxy-6 benzothiazole pour obtenir un medicament destine au traitement de la schizophrenie
US5236940A (en) * 1988-12-15 1993-08-17 Rhone-Poulenc Sante Pharmaceutical compositions, 2-benzothiazolamine derivatives, and their preparation
FR2640624B1 (fr) * 1988-12-15 1994-08-12 Rhone Poulenc Sante Medicaments a base de derives de la benzothiazolamine-2, nouveaux derives et leur preparation
EP0374041B1 (fr) * 1988-12-15 1992-06-17 Rhone-Poulenc Sante Médicaments à base de dérivés de la benzothiazolamine-2, dérivés et leur préparation
FR2649705B2 (fr) * 1989-07-13 1994-09-23 Rhone Poulenc Sante Medicaments a base de derives de la benzothiazolamine-2, nouveaux derives et leur preparation
FR2649701B2 (fr) * 1988-12-15 1991-11-22 Rhone Poulenc Sante Derives d'imino-2 benzothiazoline, leurs procedes de preparation et les medicaments les contenant
EP0375510B1 (fr) * 1988-12-15 1992-11-11 Rhone-Poulenc Sante Dérivés d'imino-2 polyfluoroalcoxy-6 benzothiazole, leurs procédés de préparation et les médicaments les contenant
DE3937271A1 (de) * 1989-11-09 1991-05-16 Boehringer Ingelheim Kg Transdermale applikation von 2-amino-6-n-propylamino-4,5,6,7-tetrahydrobenzothiazol
FR2662160B1 (fr) * 1990-05-18 1992-07-24 Rhone Poulenc Sante Derives d'alkylthio-3 propyl-3 benzothiazoline leur preparation et les medicaments les contenant.
FR2662694A1 (fr) * 1990-06-05 1991-12-06 Rhone Poulenc Sante Derives du benzoselenazole, leur preparation et les medicaments les contenant.
FR2663030A1 (fr) * 1990-06-05 1991-12-13 Rhone Poulenc Sante Derives selenies de benzothiazoline leur preparation et les medicaments les contenant.
FR2662695A1 (fr) * 1990-06-05 1991-12-06 Rhone Poulenc Sante Amino-2 polyfluoroalcoxy-6 benzoselenazoles, leur preparation et les medicaments les contenant.
FR2688138B1 (fr) * 1992-03-06 1995-05-05 Rhone Poulenc Rorer Sa Application de l'amino-2 trifluoromethoxy-6 benzothiazole pour obtenir un medicament destine au traitement de la sclerose laterale amyotrophique.
CA2097458C (en) * 1992-06-02 2004-07-20 Tameichi Ochiai Metal chelate compound and optical recording medium using the compound
FR2699077B1 (fr) * 1992-12-16 1995-01-13 Rhone Poulenc Rorer Sa Application d'anticonvulsivants dans le traitement de lésions neurologiques liées à des traumatismes.
FR2700116B1 (fr) * 1993-01-07 1995-02-03 Rhone Poulenc Rorer Sa Application d'anticonvulsivants comme radioprotecteurs.
FR2702148B1 (fr) * 1993-03-05 1995-04-07 Rhone Poulenc Rorer Sa Application d'anticonvulsivants dans le traitement du neuro-sida.
FR2714828B1 (fr) * 1994-01-12 1996-02-02 Rhone Poulenc Rorer Sa Application du riluzole dans le traitement des maladies mitochondriales.
FR2741803A1 (fr) * 1995-12-01 1997-06-06 Rhone Poulenc Rorer Sa Application de 2-aminobenzothiazoles dans le traitement de la maladie de parkinson et des syndromes parkinsoniens
SE9802360D0 (sv) * 1998-07-01 1998-07-01 Wikstroem Hakan Vilhelm New 2-aminothiazol-fused 2-aminoindans and 2-aminotetralins ((basic)-N-substituted and (basic)-N,N-disubstituted derivatives of 2,6-diamino-thiazolo(4,5-f)indan and 2,7-di-amino-thiazolo(4,5-g)tetralin
FR2787028B1 (fr) 1998-12-15 2002-10-18 Aventis Pharma Sa Utilisation du riluzole dans le traitement des traumatismes acoustiques
WO2000069838A1 (en) * 1999-05-12 2000-11-23 Neurosearch A/S Ion channel modulating agents
DE60041365D1 (de) 1999-06-04 2009-02-26 Vereniging Voor Christelijk Wetenschappelijk Onderwijs Verwendung von Riluzol zur Behandlung Multipler Sklerose
US20070092450A1 (en) * 2000-10-16 2007-04-26 Mallinckrodt Inc. Tissue-specific exogenous optical agents
US20040180809A1 (en) * 2000-10-16 2004-09-16 Mallinckrodt Inc. Tissue-specific exogenous optical agents
US6716413B1 (en) * 2000-10-16 2004-04-06 Mallinckrodt, Inc. Indole compounds as tissue-specific exogenous optical agents
EP1416931B1 (en) * 2001-08-13 2007-06-13 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Inhibitors of polyq-aggregation
EP2266590A3 (en) 2002-02-22 2011-04-20 Shire LLC Active agent delivery sytems and methods for protecting and administering active agents
AU2003257300B2 (en) * 2002-08-07 2010-01-21 Neuraxon Inc. Amino benzothiazole compounds with NOS inhibitory activity
US20040176430A1 (en) * 2002-11-21 2004-09-09 Jeffrey Sterling Propargyl-trifluoromethoxy-amino-benzothiazole derivatives
US7087761B2 (en) 2003-01-07 2006-08-08 Hoffmann-La Roche Inc. Cyclization process for substituted benzothiazole derivatives
WO2005037276A1 (en) * 2003-10-09 2005-04-28 Aventis Pharma S.A. Use of riluzole for the treatment of essential tremor
WO2005077343A2 (de) * 2004-02-11 2005-08-25 Max-Delbrück-Centrum für Molekulare Medizin Neue arzneimittel und diagnostische zusammensetzungen für behandlung und diagnose von neurodegenerativen erkrankungen und amyloid-krankheiten
US20050197365A1 (en) * 2004-02-27 2005-09-08 Jeffrey Sterling Diamino thiazoloindan derivatives and their use
US9629817B2 (en) 2005-08-25 2017-04-25 Steven Michael Weiss Reducing myocardial damage and the incidence of arrhythmia arising from loss, reduction or interruption in coronary blood flow
US7902248B2 (en) 2006-12-14 2011-03-08 Hoffmann-La Roche Inc. Oxime glucokinase activators
EP2509596B1 (en) 2009-12-08 2019-08-28 Case Western Reserve University Gamma aminoacids for treating ocular disorders
WO2015057884A1 (en) 2013-10-16 2015-04-23 The Regents Of The University Of California Methods for treating seizure disorders and pain
CN110330450B (zh) * 2019-06-12 2021-01-15 温州医科大学 一种不对称硫脲类化合物的制备方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2019529A (en) * 1935-11-05 Aminobenzothiazole compound
US1345552A (en) 1917-12-03 1920-07-06 Waldo A Rigal Combination-lock
GB1153648A (en) * 1967-03-22 1969-05-29 Twyford Lab Ltd Substituted 2-Anilino Benzothiazole Basic Ethers
LU63457A1 (el) * 1970-07-06 1971-11-12
JPS5018463A (el) * 1973-06-19 1975-02-26
DE2656468A1 (de) * 1976-12-14 1978-06-15 Boehringer Mannheim Gmbh N-(benzthiazol-2-yl)-oxamidsaeure- derivate und verfahren zu ihrer herstellung
DD149070A1 (de) * 1980-02-14 1981-06-24 Gerhard Kempter Verfahren zur herstellung von basisch substituierten acylaminoheterocyclen
DE3017976A1 (de) * 1980-05-10 1981-11-19 Dr. Karl Thomae Gmbh, 7950 Biberach Substituierte 2-amino-5-halogen-benzothiazole, verfahen zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
FR2492258A1 (fr) * 1980-10-17 1982-04-23 Pharmindustrie Nouveau medicament a base d'amino-2 trifluoromethoxy-6 benzothiazole
DE3328438A1 (de) * 1982-08-10 1984-02-16 Basf Ag, 6700 Ludwigshafen Neue oxamidsaeure-derivaten, verfahren zu ihrer herstellung und diese enthaltende therapeutische mittel
EP0186087B1 (de) * 1984-12-22 1989-08-23 Dr. Karl Thomae GmbH Tetrahydro-benzthiazole, deren Herstellung und deren Verwendung als Zwischenprodukte oder als Arnzneimittel

Also Published As

Publication number Publication date
EP0282971A3 (en) 1991-04-24
ES2065895T3 (es) 1995-03-01
DE3852555D1 (de) 1995-02-09
US4826860A (en) 1989-05-02
GR3015466T3 (en) 1995-06-30
JPS63313729A (ja) 1988-12-21
EP0282971A2 (en) 1988-09-21
ATE116134T1 (de) 1995-01-15
DE3852555T2 (de) 1995-05-04
JP2602275B2 (ja) 1997-04-23
EP0282971B1 (en) 1994-12-28

Similar Documents

Publication Publication Date Title
CA1312287C (en) Substituted 2-aminobenzothiazoles and derivatives useful as cerebrovascular agents
JP5387997B2 (ja) 血管の収縮または拡張による疾患治療剤
KR101823924B1 (ko) 안구 부종, 신생혈관화 및 관련 질환의 치료를 위한 조성물 및 방법
EP1642581B1 (en) Treatment of retinal diseases caused by impaired blood flow with quinoxaline derivatives
US11529337B2 (en) Method of treating pain
JP2000513360A (ja) Il―8レセプターアンタゴニスト
ES2426234T3 (es) Derivado de amida tiazol, procedimiento de preparación y usos del mismo
AU4182200A (en) Thiadiazolyl urea or thiourea derivatives for antiviral treatment
JPS61263917A (ja) 脳機能正常化剤
JP2001501918A (ja) Il―8レセプターアンタゴニスト
EP4025211A1 (en) Methods of treating epilepsy using the same
JP2017534673A (ja) 精神病性障害を治療するための方法および組成物
US4918090A (en) Substituted 2-aminbenzothiazoles and derivatives useful as cerebrovascular agents
JP2009001591A (ja) 緑内障治療用のデプレニル化合物
US9102636B2 (en) Analgesic compounds, compositions, and uses thereof
WO2011057110A1 (en) Gpr109a agonists for the treatment of cerebral ischemia
US4971983A (en) Substituted 2-aminobenzothiazoles and derivatives useful as cerebrovascular agents
JP2003500447A (ja) Il−8受容体アンタゴニスト
IE60267B1 (en) Centrally-acting muscle relaxants
JP2001512445A (ja) Il−8レセプターアンタゴニスト
CN113242735A (zh) 使用氨基甲酸酯化合物预防、缓解或治疗并发的癫痫发作
KR20210058592A (ko) 실데나필 및 rock 저해제를 포함하는 뇌졸중으로 인한 인지 기능 저하의 치료용 약학적 조성물
US20220296563A1 (en) Acylated active agents and methods of their use for the treatment of metabolic disorders and nonalcoholic fatty liver disease
JP2643798B2 (ja) 末梢動脈血流増加剤
JPH03128370A (ja) 新規なスルフォンアミド

Legal Events

Date Code Title Description
MKEX Expiry